Clinical Trials
3 trialsNCT04829604 2026-03-09
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Phase 2 Active not recruiting
NCT02448420 2024-04-18
PATRICIA II
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT03255070 2024-02-01
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
Phase 1 Completed